Piramal Pharma plans to double its turnover to $2 billion by 2030, focusing on its CDMO business and high-growth sectors like complex hospital generics and consumer healthcare. The company aims for significant revenue growth and improved EBITDA margins through strategic investments, expansions, and leveraging cost-efficient manufacturing infrastructure in India.
Related Posts
HPCL shares jump nearly 5% as net profit more than triples in Q3
- staff
- January 24, 2025
- 0
Hindustan Petroleum Corporation Ltd (HPCL) shares surged nearly 5% after the company posted a more than threefold increase in December quarter net profit. The profit […]
Unilever chief Schumacher out after 2-year stint, CFO elevated
- staff
- February 26, 2025
- 0
Srinivas Phatak will assume the role of Unilever’s acting CFO on March 1. Current CFO Fernando Fernandez will be elevated to CEO position. Phatak, a […]